Page 6 - Johnc Klock News Today

Sanford C. Bernstein initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) in a research note issued to investors on Tuesday, The Fly reports. The brokerage issued an underperform rating and a $81.00 price target on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. BMO Capital Markets […]

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) – Equities research analysts at William Blair issued their Q1 2023 earnings estimates for BioMarin Pharmaceutical in a report issued on Tuesday, February 28th. William Blair analyst T. Lugo expects that the biotechnology company will post earnings per share of $0.16 for the quarter. The consensus estimate for […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) had its price objective raised by equities research analysts at Credit Suisse Group from $110.00 to $127.00 in a research report issued on Tuesday, The Fly reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Credit Suisse Group’s target price suggests a potential upside of […]

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) gapped down before the market opened on Tuesday after Canaccord Genuity Group lowered their price target on the stock from $119.00 to $112.00. The stock had previously closed at $103.24, but opened at $99.30. Canaccord Genuity Group currently has a hold rating on the stock. BioMarin […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) is scheduled to be announcing its earnings results after the market closes on Monday, February 27th. Analysts expect the company to announce earnings of $0.38 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link. BioMarin Pharmaceutical Stock […]

Allianz Asset Management GmbH lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 100.0% during the 3rd quarter, Holdings Channel.com reports. The fund owned 49,454 shares of the biotechnology company’s stock after selling 170,815,053 shares during the quarter. Allianz Asset Management GmbH’s holdings in BioMarin Pharmaceutical were worth $4,191,000 as […]

National Cancer Institute prostate cancer screening study of QT Imaging’s body scanning technology indicates that its QTscan® has equal or better...

Innovative MedTech company supported by US Capital Global Securities engages ARC Group to identify SPAC partner and advise on merger....

Innovative MedTech company supported by US Capital Global Securities sees international expansion and continued success with its new medical imaging technology.